Related references
Note: Only part of the references are listed.Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
Mohammed Tanjimur Rahman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Edita Aksamitiene et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Balazs Gyoerffy et al.
ENDOCRINE-RELATED CANCER (2012)
Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples
Tibor Fekete et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance
W. Li et al.
ONCOGENE (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Jetset: selecting the optimal microarray probe set to represent a gene
Qiyuan Li et al.
BMC BIOINFORMATICS (2011)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Euan A. Stronach et al.
NEOPLASIA (2011)
MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo
Ying C. Henderson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A prognostic gene expression index in ovarian cancer - validation across different independent data sets
Carsten Denkert et al.
JOURNAL OF PATHOLOGY (2009)
Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
Ludovica Ciuffreda et al.
NEOPLASIA (2009)
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2009)
A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma
B. Gyoerffy et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Gene-expression profiling in epithelial ovarian cancer
Panagiotis A. Konstantinopoulos et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis
Alireza Mirmohammadsadegh et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
Matthew J. Hayat et al.
ONCOLOGIST (2007)
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
M. K. L. Fung et al.
BRITISH JOURNAL OF CANCER (2006)
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
Heini Lassus et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
The Akt/PKB pathway: molecular target for cancer drug discovery
JQ Cheng et al.
ONCOGENE (2005)
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
LC Hartmann et al.
CLINICAL CANCER RESEARCH (2005)
Alternative mapping of probes to genes for Affymetrix chips -: art. no. 111
L Gautier et al.
BMC BIOINFORMATICS (2004)
Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation
S Schweyer et al.
BRITISH JOURNAL OF CANCER (2004)
Gene expression signature with independent prognostic significance in epithelial ovarian cancer
D Spentzos et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Targeting the mitogen-activated protein kinase cascade to treat cancer
JS Sebolt-Leopold et al.
NATURE REVIEWS CANCER (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
G Singer et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation
PY Yeh et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Requirement for ERK activation in cisplatin-induced apoptosis
XT Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
